Alzheimer's disease stories

Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 20263 sources

Aug 14, 2026

Brain autopsies reveal fewer Alzheimer's signs in woman who took menopause drug

Autopsy findings show reduced Alzheimer's pathology in a woman who used menopause medication, suggesting potential protective effects of hormone therapy on brain health.

Aug 14, 20262 sources

Women taking estrogen-only hormone therapy showed fewer Alzheimer's signs in brain tissue

A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.

Aug 14, 20263 sources

Aug 3, 2026

APOE2 gene protects brain from Alzheimer's by reducing DNA damage

Research shows the longevity-linked APOE2 gene protects brain cells by reducing DNA damage and helping neurons recover from stress, potentially opening new treatment paths for Alzheimer's disease.

Aug 3, 20261 source

May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 20261 source

Apr 23, 2026

Dopamine Loss Emerges as Key Driver of Memory Decline in Alzheimer’s

Study finds reduced dopamine signaling contributes to memory decline in Alzheimer’s, highlighting a previously underrecognized pathway and potential target for treatment.

Apr 23, 20263 sources

Top claims

▪In Acadia's Phase 2 trial for Alzheimer's disease psychosis, a 60-milligram once-daily dose of remlifanserin showed greater improvement than placebo but did not achieve statistical significance after six weeks, while a 30-milligram once-daily dose showed little improvement compared with placebo
▪Acadia's Phase 2 trial for Alzheimer's disease psychosis showed that remlifanserin had rates of side effects and treatment discontinuations similar to placebo, with no apparent adverse effects on movement or cognitive function and zero reported deaths
▪Remlifanserin achieved statistical significance on a key secondary measure evaluating the overall severity of Alzheimer's disease psychosis symptoms during Acadia's Phase 2 trial

Subtopics

Alzheimer’s & dementia6 Mental health6 Drug Approval and Clinical Trials3 Brain health & dementia researchers2 Brain longevity2 Clinical trials2 Neuroprotection2 Reproductive Health2 Aging (Biology)1 Dopamine1 Drug development1 Hormone optimization1 Longevity & aging1 Memory & focus1 Menopause1 Neuroscience1 Pharma1 Preventive medicine1 Women’s mental health1

Related timelines